Cardiac natriuretic peptides.
Animals
Atrial Appendage
/ cytology
Atrial Fibrillation
/ metabolism
Atrial Natriuretic Factor
/ genetics
Atrial Remodeling
Biomarkers
/ metabolism
Cyclic GMP
/ metabolism
Diabetes Mellitus
/ metabolism
Fibrosis
Gene Expression Regulation, Developmental
Heart Atria
/ cytology
Heart Failure
/ metabolism
Humans
Hypertension
/ metabolism
Lipid Metabolism
/ physiology
Metabolic Syndrome
/ metabolism
Mice
Myocardium
/ metabolism
Myocytes, Cardiac
/ metabolism
Natriuretic Peptide, Brain
/ genetics
Obesity
/ metabolism
Peptide Fragments
/ metabolism
Prognosis
Protein Processing, Post-Translational
Pulmonary Arterial Hypertension
/ metabolism
Receptors, Guanylate Cyclase-Coupled
/ metabolism
Secretory Vesicles
/ metabolism
Ventricular Remodeling
Water-Electrolyte Balance
/ physiology
Journal
Nature reviews. Cardiology
ISSN: 1759-5010
Titre abrégé: Nat Rev Cardiol
Pays: England
ID NLM: 101500075
Informations de publication
Date de publication:
11 2020
11 2020
Historique:
accepted:
06
04
2020
pubmed:
24
5
2020
medline:
27
10
2020
entrez:
24
5
2020
Statut:
ppublish
Résumé
Investigations into the mixed muscle-secretory phenotype of cardiomyocytes from the atrial appendages of the heart led to the discovery that these cells produce, in a regulated manner, two polypeptide hormones - the natriuretic peptides - referred to as atrial natriuretic factor or atrial natriuretic peptide (ANP) and brain or B-type natriuretic peptide (BNP), thereby demonstrating an endocrine function for the heart. Studies on the gene encoding ANP (NPPA) initiated the field of modern research into gene regulation in the cardiovascular system. Additionally, ANP and BNP were found to be the natural ligands for cell membrane-bound guanylyl cyclase receptors that mediate the effects of natriuretic peptides through the generation of intracellular cGMP, which interacts with specific enzymes and ion channels. Natriuretic peptides have many physiological actions and participate in numerous pathophysiological processes. Important clinical entities associated with natriuretic peptide research include heart failure, obesity and systemic hypertension. Plasma levels of natriuretic peptides have proven to be powerful diagnostic and prognostic biomarkers of heart disease. Development of pharmacological agents that are based on natriuretic peptides is an area of active research, with vast potential benefits for the treatment of cardiovascular disease.
Identifiants
pubmed: 32444692
doi: 10.1038/s41569-020-0381-0
pii: 10.1038/s41569-020-0381-0
doi:
Substances chimiques
Biomarkers
0
Peptide Fragments
0
midregional pro-atrial natriuretic peptide, human
0
pro-brain natriuretic peptide (1-76)
0
Natriuretic Peptide, Brain
114471-18-0
Atrial Natriuretic Factor
85637-73-6
Receptors, Guanylate Cyclase-Coupled
EC 4.6.1.2
Cyclic GMP
H2D2X058MU
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
698-717Références
McGrath, M. F., de Bold, M. L. & de Bold, A. J. The endocrine function of the heart. Trends Endocrinol. Metab. 16, 469–477 (2005).
pubmed: 16269246
doi: 10.1016/j.tem.2005.10.007
Jamieson, J. D. & Palade, G. E. Specific granules in atrial muscle cells. J. Cell Biol. 23, 151–172 (1964).
pubmed: 14228508
pmcid: 2106511
doi: 10.1083/jcb.23.1.151
de Bold, A. J., Borenstein, H. B., Veress, A. T. & Sonnenberg, H. A rapid and potent natriuretic response to intravenous injection of atrial myocardial extracts in rats. Life Sci. 28, 89–94 (1981).
pubmed: 7219045
doi: 10.1016/0024-3205(81)90370-2
Flynn, T. G., de Bold, M. L. & de Bold, A. J. The amino acid sequence of an atrial peptide with potent diuretic and natriuretic properties. Biochem. Biophys. Res. Commun. 117, 859–865 (1983).
pubmed: 6230081
doi: 10.1016/0006-291X(83)91675-3
Dzau, V. J. et al. Nomenclature for atrial peptides. N. Engl. J. Med. 316, 1278–1279 (1987).
pubmed: 2952880
doi: 10.1056/NEJM198705143162018
Sudoh, T., Kangawa, K., Minamino, N. & Matsuo, H. A new natriuretic peptide in porcine brain. Nature 332, 78–81 (1988).
pubmed: 2964562
doi: 10.1038/332078a0
Sudoh, T., Minamino, N., Kangawa, K. & Matsuo, H. C-type natriuretic peptide (CNP): a new member of natriuretic peptide family identified in porcine brain. Biochem. Biophys. Res. Commun. 168, 863–870 (1990).
pubmed: 2139780
doi: 10.1016/0006-291X(90)92401-K
Komatsu, Y. et al. C-type natriuretic peptide (CNP) in rats and humans. Endocrinology 129, 1104–1106 (1991).
pubmed: 1855454
doi: 10.1210/endo-129-2-1104
Nishimura, M. et al. Roles of brain angiotensin II and C-type natriuretic peptide in deoxycorticosterone acetate-salt hypertension in rats. J. Hypertens. 16, 1175–1185 (1998).
pubmed: 9794722
Ueda, S. et al. Distribution and characterization of immunoreactive porcine C-type natriuretic peptide. Biochem. Biophys. Res. Commun. 175, 759–767 (1991).
pubmed: 1827257
doi: 10.1016/0006-291X(91)91631-L
Furuya, M. et al. C-type natriuretic peptide is a growth inhibitor of rat vascular smooth muscle cells. Biochem. Biophys. Res. Commun. 177, 927–931 (1991).
pubmed: 1647770
doi: 10.1016/0006-291X(91)90627-J
Prickett, T. C. et al. C-type natriuretic peptides in coronary disease. Clin. Chem. 63, 316–324 (2017).
pubmed: 28062626
doi: 10.1373/clinchem.2016.257816
Wright, S. P. et al. Amino-terminal pro-C-type natriuretic peptide in heart failure. Hypertension 43, 94–100 (2004).
pubmed: 14656955
doi: 10.1161/01.HYP.0000105623.04382.C0
Moyes, A. J. & Hobbs, A. J. C-type natriuretic peptide: a multifaceted paracrine regulator in the heart and vasculature. Int. J. Mol. Sci. 20, 2281 (2019).
pmcid: 6539462
doi: 10.3390/ijms20092281
Zeller, R., Bloch, K. D., Williams, B. S., Arceci, R. J. & Seidman, C. E. Localized expression of the atrial natriuretic factor gene during cardiac embryogenesis. Genes Dev. 1, 693–698 (1987).
pubmed: 2962900
doi: 10.1101/gad.1.7.693
Bruneau, B. G. et al. A murine model of Holt-Oram syndrome defines roles of the T-box transcription factor Tbx5 in cardiogenesis and disease. Cell 106, 709–721 (2001).
pubmed: 11572777
doi: 10.1016/S0092-8674(01)00493-7
Durocher, D., Chen, C. Y., Ardati, A., Schwartz, R. J. & Nemer, M. The atrial natriuretic factor promoter is a downstream target for Nkx-2.5 in the myocardium. Mol. Cell. Biol. 16, 4648–4655 (1996).
pubmed: 8756621
pmcid: 231464
doi: 10.1128/MCB.16.9.4648
Durocher, D., Charron, F., Warren, R., Schwartz, R. J. & Nemer, M. The cardiac transcription factors Nkx2-5 and GATA-4 are mutual cofactors. EMBO J. 16, 5687–5696 (1997).
pubmed: 9312027
pmcid: 1170200
doi: 10.1093/emboj/16.18.5687
Välimaki, M. J. & Ruskoaho, H. J. Targeting GATA4 for cardiac repair. IUBMB Life 72, 68–79 (2020).
pubmed: 31419020
doi: 10.1002/iub.2150
Tanaka, M., Chen, Z., Bartunkova, S., Yamasaki, N. & Izumo, S. The cardiac homeobox gene Csx/Nkx2.5 lies genetically upstream of multiple genes essential for heart development. Development 126, 1269–1280 (1999).
pubmed: 10021345
doi: 10.1242/dev.126.6.1269
Lickert, H. et al. Baf60c is essential for function of BAF chromatin remodelling complexes in heart development. Nature 432, 107–112 (2004).
pubmed: 15525990
doi: 10.1038/nature03071
Habets, P. E. et al. Cooperative action of Tbx2 and Nkx2.5 inhibits ANF expression in the atrioventricular canal: implications for cardiac chamber formation. Genes Dev. 16, 1234–1246 (2002).
pubmed: 12023302
pmcid: 186286
doi: 10.1101/gad.222902
Horsthuis, T. et al. Distinct regulation of developmental and heart disease-induced atrial natriuretic factor expression by two separate distal sequences. Circ. Res. 102, 849–859 (2008).
pubmed: 18276916
doi: 10.1161/CIRCRESAHA.107.170571
Sergeeva, I. A. et al. Identification of a regulatory domain controlling the Nppa-Nppb gene cluster during heart development and stress. Development 143, 2135–2146 (2016).
pubmed: 27048739
Zaidi, S. & Brueckner, M. Genetics and genomics of congenital heart disease. Circ. Res. 120, 923–940 (2017).
pubmed: 28302740
pmcid: 5557504
doi: 10.1161/CIRCRESAHA.116.309140
Mori, T. et al. Volume overload results in exaggerated cardiac hypertrophy in the atrial natriuretic peptide knockout mouse. Cardiovasc. Res. 61, 771–779 (2004).
pubmed: 14985074
doi: 10.1016/j.cardiores.2003.12.005
Takeuchi, J. K. et al. Chromatin remodelling complex dosage modulates transcription factor function in heart development. Nat. Commun. 2, 187 (2011).
pubmed: 21304516
doi: 10.1038/ncomms1187
Koshiba-Takeuchi, K. et al. Reptilian heart development and the molecular basis of cardiac chamber evolution. Nature 461, 95–98 (2009).
pubmed: 19727199
pmcid: 2753965
doi: 10.1038/nature08324
Luna-Zurita, L. et al. Complex interdependence regulates heterotypic transcription factor distribution and coordinates cardiogenesis. Cell 164, 999–1014 (2016).
pubmed: 26875865
pmcid: 4769693
doi: 10.1016/j.cell.2016.01.004
Ogawa, T. & de Bold, A. J. Uncoordinated regulation of atrial natriuretic factor and brain natriuretic peptide in lipopolysaccharide-treated rats. Biomarkers 17, 140–149 (2012).
pubmed: 22224641
doi: 10.3109/1354750X.2011.643487
Ogawa, T., Veinot, J. P., Kuroski de Bold, M. L., Georgalis, T. & de Bold, A. J. Angiotensin II receptor antagonism reverts the selective cardiac BNP upregulation and secretion observed in myocarditis. Am. J. Physiol. Heart Circ. Physiol. 294, H2596–H2603 (2008).
pubmed: 18408131
doi: 10.1152/ajpheart.00215.2008
Ma, K. K., Ogawa, T. & de Bold, A. J. Selective upregulation of cardiac brain natriuretic peptide at the transcriptional and translational levels by pro-inflammatory cytokines and by conditioned medium derived from mixed lymphocyte reactions via p38 MAP kinase. J. Mol. Cell. Cardiol. 36, 505–513 (2004).
pubmed: 15081310
doi: 10.1016/j.yjmcc.2004.01.001
Ma, K. K., Banas, K. & de Bold, A. J. Determinants of inducible brain natriuretic peptide promoter activity. Regul. Pept. 128, 169–176 (2005).
pubmed: 15837525
doi: 10.1016/j.regpep.2004.12.025
Yasuda, S. & Lew, W. Y. Lipopolysaccharide depresses cardiac contractility and β-adrenergic contractile response by decreasing myofilament response to Ca
pubmed: 9400382
doi: 10.1161/01.RES.81.6.1011
Tomaru, K. K. et al. Transcriptional activation of the BNP gene by lipopolysaccharide is mediated through GATA elements in neonatal rat cardiac myocytes. J. Mol. Cell. Cardiol. 34, 649–659 (2002).
doi: 10.1006/jmcc.2002.2005
Pemberton, C. J. et al. First identification of circulating prepro-A-type natriuretic peptide (preproANP) signal peptide fragments in humans: initial assessment as cardiovascular biomarkers. Clin. Chem. 58, 757–767 (2012).
pubmed: 22291141
doi: 10.1373/clinchem.2011.176990
Siriwardena, M. et al. B-type natriuretic peptide signal peptide circulates in human blood: evaluation as a potential biomarker of cardiac ischemia. Circulation 122, 255–264 (2010).
pubmed: 20606123
doi: 10.1161/CIRCULATIONAHA.109.909937
Schellenberger, U. et al. The precursor to B-type natriuretic peptide is an O-linked glycoprotein. Arch. Biochem. Biophys. 451, 160–166 (2006).
pubmed: 16750161
doi: 10.1016/j.abb.2006.03.028
Seferian, K. R. et al. Immunodetection of glycosylated NT-proBNP circulating in human blood. Clin. Chem. 54, 866–873 (2008).
pubmed: 18339697
doi: 10.1373/clinchem.2007.100040
Crimmins, D. L. & Kao, J. L. A glycosylated form of the human cardiac hormone pro B-type natriuretic peptide is an intrinsically unstructured monomeric protein. Arch. Biochem. Biophys. 475, 36–41 (2008).
pubmed: 18440296
pmcid: 2659528
doi: 10.1016/j.abb.2008.04.007
Semenov, A. G. et al. Processing of pro-brain natriuretic peptide is suppressed by O-glycosylation in the region close to the cleavage site. Clin. Chem. 55, 489–498 (2009).
pubmed: 19168558
doi: 10.1373/clinchem.2008.113373
Goetze, J. P. B-type natriuretic peptide: from posttranslational processing to clinical measurement. Clin. Chem. 58, 83–91 (2012).
pubmed: 22126935
doi: 10.1373/clinchem.2011.165696
Hansen, L. H. et al. Discovery of O-glycans on atrial natriuretic peptide (ANP) that affect both its proteolytic degradation and potency at its cognate receptor. J. Biol. Chem. 294, 12567–12578 (2019).
pubmed: 31186350
pmcid: 6709625
doi: 10.1074/jbc.RA119.008102
Dries, D. L. et al. Corin gene minor allele defined by 2 missense mutations is common in blacks and associated with high blood pressure and hypertension. Circulation 112, 2403–2410 (2005).
pubmed: 16216958
doi: 10.1161/CIRCULATIONAHA.105.568881
Semenov, A. G. et al. Processing of pro-B-type natriuretic peptide: furin and corin as candidate convertases. Clin. Chem. 56, 1166–1176 (2010).
pubmed: 20489134
doi: 10.1373/clinchem.2010.143883
Yan, W., Wu, F., Morser, J. & Wu, Q. Corin, a transmembrane cardiac serine protease, acts as a pro-atrial natriuretic peptide-converting enzyme. Proc. Natl Acad. Sci. USA 97, 8525–8529 (2000).
pubmed: 10880574
doi: 10.1073/pnas.150149097
pmcid: 26981
Ogawa, T., Vatta, M., Bruneau, B. G. & de Bold, A. J. Characterization of natriuretic peptide production by adult heart atria. Am. J. Physiol. Heart Circ. Physiol. 276, H1977–H1986 (1999).
doi: 10.1152/ajpheart.1999.276.6.H1977
Mangat, H. & de Bold, A. J. Stretch-induced atrial natriuretic factor release utilizes a rapidly depleting pool of newly synthesized hormone. Endocrinology 133, 1398–1403 (1993).
pubmed: 8365374
doi: 10.1210/endo.133.3.8365374
Arvan, P. & Halban, P. A. Sorting ourselves out: seeking consensus on trafficking in the beta-cell. Traffic 5, 53–61 (2004).
pubmed: 14675425
doi: 10.1111/j.1600-0854.2004.00152.x
de Bold, A. J. Heart atria granularity effects of changes in water-electrolyte balance. Proc. Soc. Exp. Biol. Med. 161, 508–511 (1979).
pubmed: 482282
doi: 10.3181/00379727-161-40584
Bensimon, M. A. & de Bold, A. J. Role of Gi/o protein signalling in ANF stretch-secretion coupling in heart atria [abstract]. J. Mol. Cell. Cardiol. 33, A11 (2001).
doi: 10.1016/S0022-2828(01)90042-2
Bensimon, M. et al. Participation of G proteins in natriuretic peptide hormone secretion from heart atria. Endocrinology 145, 5313–5321 (2004).
pubmed: 15308619
doi: 10.1210/en.2004-0698
McGrath, M. F. & de Bold, A. J. Transcriptional analysis of the mammalian heart with special reference to its endocrine function. BMC Genomics 10, 254 (2009).
pubmed: 19486520
pmcid: 2694839
doi: 10.1186/1471-2164-10-254
Chang, A. I., McGrath, M. F. & de Bold, A. J. Phospholipase C signaling tonically represses basal atrial natriuretic factor secretion from the atria of the heart. Am. J. Physiol. Heart Circ. Physiol. 304, H1328–H1336 (2013).
pubmed: 23479262
doi: 10.1152/ajpheart.00847.2012
Roeske, C. et al. Go protein subunit Goα and the secretory process of the natriuretic peptide hormones ANF and BNP. J. Mol. Endocrinol. 54, 277–288 (2015).
pubmed: 25917834
doi: 10.1530/JME-15-0081
Ogawa, T. et al. Neuroendocrine profiling of humans receiving cardiac allografts. J. Heart Lung Transplant. 24, 1046–1054 (2005).
pubmed: 16102440
doi: 10.1016/j.healun.2004.06.023
Ramos, H. & de Bold, A. J. Gene expression, processing and secretion of natriuretic peptides: physiologic and diagnostic implications. Heart Fail. Clin. 2, 255–268 (2006).
pubmed: 17386895
doi: 10.1016/j.hfc.2006.08.005
Ogawa, T. et al. Evidence for load-dependent and load-independent determinants of cardiac natriuretic peptide production. Circulation 93, 2059–2067 (1996).
pubmed: 8640983
doi: 10.1161/01.CIR.93.11.2059
Yokota, N. et al. Dissociation of cardiac hypertrophy, myosin heavy chain isoform expression, and natriuretic peptide production in DOCA-salt rats. Am. J. Hypertens. 8, 301–310 (1995).
pubmed: 7540847
doi: 10.1016/0895-7061(94)00210-3
Murakami, Y. et al. New insights into the mechanism of the elevation of plasma brain natriuretic polypeptide levels in patients with left ventricular hypertrophy. Can. J. Cardiol. 18, 1294–1300 (2002).
pubmed: 12518181
Masters, R. G. et al. Discoordinate modulation of natriuretic peptides during acute cardiac allograft rejection in humans. Circulation 100, 287–291 (1999).
pubmed: 10411854
doi: 10.1161/01.CIR.100.3.287
McGrath, M. F. & de Bold, A. J. Determinants of natriuretic peptide gene expression. Peptides 26, 933–943 (2005).
pubmed: 15911063
doi: 10.1016/j.peptides.2004.12.022
de Bold, M. L., Etchepare, A., Martinuk, A. & de Bold, A. J. Cardiac hormones ANF and BNP modulate proliferation in the unidirectional mixed lymphocyte reaction. J. Heart Lung Transplant. 29, 323–326 (2010).
pubmed: 19783165
doi: 10.1016/j.healun.2009.07.008
Liu, S., Chirkov, Y. Y. & Horowitz, J. D. Neutrophil-initiated myocardial inflammation and its modulation by B-type natriuretic peptide: a potential therapeutic target. Int. J. Mol. Sci. 20, E129 (2018).
pubmed: 30602672
doi: 10.3390/ijms20010129
Mohapatra, S. S. Role of natriuretic peptide signaling in modulating asthma and inflammation. Can. J. Physiol. Pharmacol. 85, 754–759 (2007).
pubmed: 17823639
doi: 10.1139/Y07-066
Suganami, T. et al. Overexpression of brain natriuretic peptide in mice ameliorates immune-mediated renal injury. J. Am. Soc. Nephrol. 12, 2652–2663 (2001).
pubmed: 11729234
doi: 10.1681/ASN.V12122652
Vollmar, A. M. The role of atrial natriuretic peptide in the immune system. Peptides 26, 1086–1094 (2005).
pubmed: 15911076
doi: 10.1016/j.peptides.2004.08.034
Murad, F., Leitman, D. C., Bennett, B. M., Molina, C. & Waldman, S. A. Regulation of guanylate cyclase by atrial natriuretic factor and the role of cyclic GMP in vasodilation. Am. J. Med. Sci. 294, 139–143 (1987).
pubmed: 2889359
doi: 10.1097/00000441-198709000-00003
Chinkers, M. & Garbers, D. L. The protein kinase domain of the ANP receptor is required for signaling. Science 245, 1392–1394 (1989).
pubmed: 2571188
doi: 10.1126/science.2571188
Kumar, R., Grammatikakis, N. & Chinkers, M. Regulation of the atrial natriuretic peptide receptor by heat shock protein 90 complexes. J. Biol. Chem. 276, 11371–11375 (2001).
pubmed: 11152473
doi: 10.1074/jbc.M010480200
Potter, L. R. & Garbers, D. L. Dephosphorylation of the guanylyl cyclase-A receptor causes desensitization. J. Biol. Chem. 267, 14531–14534 (1992).
pubmed: 1353076
doi: 10.1016/S0021-9258(18)42069-8
Leitman, D. C. et al. Atrial natriuretic peptide, oxytocin, and vasopressin increase guanosine 3′,5′-monophosphate in LLC-PK1 kidney epithelial cells. Endocrinology 122, 1478–1485 (1988).
pubmed: 2894298
doi: 10.1210/endo-122-4-1478
McCoy, D. E., Guggino, S. E. & Stanton, B. A. The renal cGMP-gated cation channel: its molecular structure and physiological role. Kidney Int. 48, 1125–1133 (1995).
pubmed: 8569074
doi: 10.1038/ki.1995.396
Kuhn, M. Molecular physiology of natriuretic peptide signalling. Basic Res. Cardiol. 99, 76–82 (2004).
pubmed: 14963665
doi: 10.1007/s00395-004-0460-0
Miyagi, M. & Misono, K. S. Disulfide bond structure of the atrial natriuretic peptide receptor extracellular domain: conserved disulfide bonds among guanylate cyclase-coupled receptors. Biochim. Biophys. Acta 1478, 30–38 (2000).
pubmed: 10719172
doi: 10.1016/S0167-4838(00)00002-9
Miyagi, M., Zhang, X. & Misono, K. S. Glycosylation sites in the atrial natriuretic peptide receptor oligosaccharide structures are not required for hormone binding. Eur. J. Biochem. 267, 5758–5768 (2000).
pubmed: 10971587
doi: 10.1046/j.1432-1327.2000.01647.x
Potter, L. R. & Hunter, T. Phosphorylation of the kinase homology domain is essential for activation of the A-type natriuretic peptide receptor. Mol. Cell. Biol. 18, 2164–2172 (1998).
pubmed: 9528788
pmcid: 121455
doi: 10.1128/MCB.18.4.2164
Potter, L. R., Yoder, A. R., Flora, D. R., Antos, L. K. & Dickey, D. M. in cGMP: Generators, Effectors and Therapeutic Implications (eds Schmidt, H. H. H. W., Hofmann, F. & Stasch, J. P.) 341–366 (Springer, 2009).
Del Ry, S., Passino, C., Emdin, M. & Giannessi, D. C-type natriuretic peptide and heart failure. Pharmacol. Res. 54, 326–333 (2006).
pubmed: 16904335
doi: 10.1016/j.phrs.2006.06.011
Garg, R. & Pandey, K. N. Regulation of guanylyl cyclase/natriuretic peptide receptor-A gene expression. Peptides 26, 1009–1023 (2005).
pubmed: 15911069
doi: 10.1016/j.peptides.2004.09.022
John, S. W. et al. Genetic decreases in atrial natriuretic peptide and salt-sensitive hypertension. Science 267, 679–681 (1995).
pubmed: 7839143
doi: 10.1126/science.7839143
Tamura, N. et al. Critical roles of the guanylyl cyclase B receptor in endochondral ossification and development of female reproductive organs. Proc. Natl Acad. Sci. USA 101, 17300–17305 (2004).
pubmed: 15572448
doi: 10.1073/pnas.0407894101
pmcid: 534612
Rose, R. A. & Giles, W. R. Natriuretic peptide C receptor signalling in the heart and vasculature. J. Physiol. 586, 353–366 (2008).
pubmed: 18006579
doi: 10.1113/jphysiol.2007.144253
Moffatt, P. et al. Osteocrin is a specific ligand of the natriuretic peptide clearance receptor that modulates bone growth. J. Biol. Chem. 282, 36454–36462 (2007).
pubmed: 17951249
doi: 10.1074/jbc.M708596200
Matsukawa, N. et al. The natriuretic peptide clearance receptor locally modulates the physiological effects of the natriuretic peptide system. Proc. Natl Acad. Sci. USA 96, 7403–7408 (1999).
pubmed: 10377427
doi: 10.1073/pnas.96.13.7403
pmcid: 22098
Ibrahim, N. & Januzzi, J. L. The potential role of natriuretic peptides and other biomarkers in heart failure diagnosis, prognosis and management. Expert Rev. Cardiovasc. Ther. 13, 1017–1030 (2015).
pubmed: 26198476
doi: 10.1586/14779072.2015.1071664
Vodovar, N. et al. Evolution of natriuretic peptide biomarkers in heart failure: implications for clinical care and clinical trials. Int. J. Cardiol. 254, 215–221 (2018).
pubmed: 29407093
doi: 10.1016/j.ijcard.2017.11.001
Thibault, G. et al. NH2-terminal fragment of rat pro-atrial natriuretic factor in the circulation: identification, radioimmunoassay and half-life. Peptides 9, 47–53 (1988).
pubmed: 2966345
doi: 10.1016/0196-9781(88)90008-3
Holmes, S. J., Espiner, E. A., Richards, A. M., Yandle, T. G. & Frampton, C. Renal, endocrine, and hemodynamic effects of human brain natriuretic peptide in normal man. J. Clin. Endocrinol. Metab. 76, 91–96 (1993).
pubmed: 8380606
Cui, K., Huang, W., Fan, J. & Lei, H. Midregional pro-atrial natriuretic peptide is a superior biomarker to N-terminal pro-B-type natriuretic peptide in the diagnosis of heart failure patients with preserved ejection fraction. Medicine 97, e12277 (2018).
pubmed: 30200170
pmcid: 6133645
doi: 10.1097/MD.0000000000012277
Gangnus, T. & Burckhardt, B. B. Potential and limitations of atrial natriuretic peptide as biomarker in pediatric heart failure — a comparative review. Front. Pediatr. 6, 420 (2018).
pubmed: 30761275
doi: 10.3389/fped.2018.00420
Idzikowska, K. & Zielinska, M. Midregional pro-atrial natriuretic peptide, an important member of the natriuretic peptide family: potential role in diagnosis and prognosis of cardiovascular disease. J. Int. Med. Res. 46, 3017–3029 (2018).
pubmed: 30027789
pmcid: 6134641
doi: 10.1177/0300060518786907
Roberts, E. et al. The diagnostic accuracy of the natriuretic peptides in heart failure: systematic review and diagnostic meta-analysis in the acute care setting. BMJ 350, h910 (2015).
pubmed: 25740799
pmcid: 4353288
doi: 10.1136/bmj.h910
Troughton, R. W. et al. Effect of B-type natriuretic peptide-guided treatment of chronic heart failure on total mortality and hospitalization: an individual patient meta-analysis. Eur. Heart J. 35, 1559–1567 (2014).
pubmed: 24603309
pmcid: 4057643
doi: 10.1093/eurheartj/ehu090
Volpe, M., Battistoni, A. & Rubattu, S. Natriuretic peptides in heart failure: current achievements and future perspectives. Int. J. Cardiol. 281, 186–189 (2019).
pubmed: 30545616
doi: 10.1016/j.ijcard.2018.04.045
Yancy, C. W. et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 128, e240–e327 (2013).
pubmed: 23741058
Saenger, A. K. et al. Specificity of B-type natriuretic peptide assays: cross-reactivity with different BNP, NT-proBNP, and proBNP peptides. Clin. Chem. 63, 351–358 (2017).
pubmed: 28062628
doi: 10.1373/clinchem.2016.263749
Semenov, A. G. et al. Searching for a BNP standard: glycosylated proBNP as a common calibrator enables improved comparability of commercial BNP immunoassays. Clin. Biochem. 50, 181–185 (2017).
pubmed: 27823960
doi: 10.1016/j.clinbiochem.2016.11.003
Vasile, V. C. & Jaffe, A. S. Natriuretic peptides and analytical barriers. Clin. Chem. 63, 50–58 (2017).
pubmed: 28062611
doi: 10.1373/clinchem.2016.254714
Mueller, C. et al. Heart Failure Association of the European Society of Cardiology practical guidance on the use of natriuretic peptide concentrations. Eur. J. Heart Fail. 21, 715–731 (2019).
pubmed: 31222929
doi: 10.1002/ejhf.1494
Yancy, C. W. et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines and the Heart Failure Society of America. J. Am. Coll. Cardiol. 70, 776–803 (2017).
pubmed: 28461007
doi: 10.1016/j.jacc.2017.04.025
Clerico, A., Passino, C. & Emdin, M. When gonads talk to the heart sex hormones and cardiac endocrine function. J. Am. Coll. Cardiol. 58, 627–628 (2011).
pubmed: 21798426
doi: 10.1016/j.jacc.2011.03.043
Taki, M. et al. Sex differences in the prognostic power of brain natriuretic peptide and N-terminal pro-brain natriuretic peptide for cardiovascular events — the Japan morning surge-home blood pressure study. Circ. J. 82, 2096–2102 (2018).
pubmed: 29925742
doi: 10.1253/circj.CJ-18-0375
Krim, S. R. et al. Racial/ethnic differences in B-type natriuretic peptide levels and their association with care and outcomes among patients hospitalized with heart failure: findings from Get With The Guidelines-Heart Failure. JACC Heart Fail. 1, 345–352 (2013).
pubmed: 24621938
doi: 10.1016/j.jchf.2013.04.008
Redfield, M. M. et al. Plasma brain natriuretic peptide concentration: impact of age and gender. J. Am. Coll. Cardiol. 40, 976–982 (2002).
pubmed: 12225726
doi: 10.1016/S0735-1097(02)02059-4
Ibrahim, I. et al. Superior performance of N-terminal pro brain natriuretic peptide for diagnosis of acute decompensated heart failure in an Asian compared with a Western setting. Eur. J. Heart Fail. 19, 209–217 (2017).
pubmed: 27620387
doi: 10.1002/ejhf.612
Madamanchi, C., Alhosaini, H., Sumida, A. & Runge, M. S. Obesity and natriuretic peptides, BNP and NT-proBNP: mechanisms and diagnostic implications for heart failure. Int. J. Cardiol. 176, 611–617 (2014).
pubmed: 25156856
pmcid: 4201035
doi: 10.1016/j.ijcard.2014.08.007
Srisawasdi, P., Vanavanan, S., Charoenpanichkit, C. & Kroll, M. H. The effect of renal dysfunction on BNP, NT-proBNP, and their ratio. Am. J. Clin. Pathol. 133, 14–23 (2010).
pubmed: 20023254
doi: 10.1309/AJCP60HTPGIGFCNK
Davidovski, F. S. & Goetze, J. P. ProANP and proBNP in plasma as biomarkers of heart failure. Biomark. Med. 13, 1129–1135 (2019).
pubmed: 31468978
doi: 10.2217/bmm-2019-0158
Maisel, A. et al. Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial. J. Am. Coll. Cardiol. 55, 2062–2076 (2010).
pubmed: 20447528
doi: 10.1016/j.jacc.2010.02.025
Odermatt, J. et al. The natriuretic peptide MR-proANP predicts all-cause mortality and adverse outcome in community patients: a 10-year follow-up study. Clin. Chem. Lab. Med. 55, 1407–1416 (2017).
pubmed: 28107168
doi: 10.1515/cclm-2016-0760
Lindberg, S. et al. MR-proANP improves prediction of mortality and cardiovascular events in patients with STEMI. Eur. J. Prev. Cardiol. 22, 693–700 (2015).
pubmed: 24906365
doi: 10.1177/2047487314538856
Salo, P. P. et al. Genome-wide association study implicates atrial natriuretic peptide rather than B-type natriuretic peptide in the regulation of blood pressure in the general population. Circ. Cardiovasc. Genet. 10, e001713 (2017).
pubmed: 29237677
pmcid: 6072381
doi: 10.1161/CIRCGENETICS.117.001713
Matsuo, A., Nagai-Okatani, C., Nishigori, M., Kangawa, K. & Minamino, N. Natriuretic peptides in human heart: novel insight into their molecular forms, functions, and diagnostic use. Peptides 111, 3–17 (2019).
pubmed: 30120963
doi: 10.1016/j.peptides.2018.08.006
Costello-Boerrigter, L. C. et al. Secretion of prohormone of B-type natriuretic peptide, proBNP1-108, is increased in heart failure. JACC Heart Fail. 1, 207–212 (2013).
pubmed: 24621871
pmcid: 4120112
doi: 10.1016/j.jchf.2013.03.001
Huntley, B. K. et al. Pro-B-type natriuretic peptide-1-108 processing and degradation in human heart failure. Circ. Heart Fail. 8, 89–97 (2015).
pubmed: 25339504
doi: 10.1161/CIRCHEARTFAILURE.114.001174
Rubattu, S. & Volpe, M. Natriuretic peptides in the cardiovascular system: multifaceted roles in physiology, pathology and therapeutics. Int. J. Mol. Sci. 20, E3991 (2019).
pubmed: 31426320
doi: 10.3390/ijms20163991
de Oliveira, I. M., Oliveira, B. D., Scanavacca, M. I. & Gutierrez, P. S. Fibrosis, myocardial crossings, disconnections, abrupt turns, and epicardial reflections: do they play an actual role in human permanent atrial fibrillation? A controlled necropsy study. Cardiovasc. Pathol. 22, 65–69 (2013).
pubmed: 22917538
doi: 10.1016/j.carpath.2012.06.001
Goldman, M. E. et al. Pathophysiologic correlates of thromboembolism in nonvalvular atrial fibrillation: I. Reduced flow velocity in the left atrial appendage (the Stroke Prevention in Atrial Fibrillation [SPAF-III] study). J. Am. Soc. Echocardiogr. 12, 1080–1087 (1999).
pubmed: 10588784
doi: 10.1016/S0894-7317(99)70105-7
Breitenstein, A. et al. Increased prothrombotic profile in the left atrial appendage of atrial fibrillation patients. Int. J. Cardiol. 185, 250–255 (2015).
pubmed: 25814212
doi: 10.1016/j.ijcard.2015.03.092
Schnabel, R. B. et al. Multiple biomarkers and atrial fibrillation in the general population. PLoS One 9, e112486 (2014).
pubmed: 25401728
pmcid: 4234420
doi: 10.1371/journal.pone.0112486
Zuo, K. et al. Correlation of left atrial wall thickness and atrial remodeling in atrial fibrillation: study based on low-dose-ibutilide-facilitated catheter ablation. Medicine 98, e15170 (2019).
pubmed: 30985700
pmcid: 6485781
doi: 10.1097/MD.0000000000015170
Hijazi, Z. et al. Cardiac biomarkers are associated with an increased risk of stroke and death in patients with atrial fibrillation: a randomized evaluation of long-term anticoagulation therapy (RE-LY) substudy. Circulation 125, 1605–1616 (2012).
pubmed: 22374183
doi: 10.1161/CIRCULATIONAHA.111.038729
Hijazi, Z. et al. N-terminal pro-B-type natriuretic peptide for risk assessment in patients with atrial fibrillation: insights from the ARISTOTLE trial (apixaban for the prevention of stroke in subjects with atrial fibrillation). J. Am. Coll. Cardiol. 61, 2274–2284 (2013).
pubmed: 23563134
doi: 10.1016/j.jacc.2012.11.082
Hijazi, Z. et al. Repeated measurements of cardiac biomarkers in atrial fibrillation and validation of the ABC stroke score over time. J. Am. Heart Assoc. 6, e004851 (2017).
pubmed: 28645934
pmcid: 5669148
doi: 10.1161/JAHA.116.004851
Ruff, C. T. et al. Cardiovascular biomarker score and clinical outcomes in patients with atrial fibrillation: a subanalysis of the ENGAGE AF-TIMI 48 randomized clinical trial. JAMA Cardiol. 1, 999–1006 (2016).
pubmed: 27706467
doi: 10.1001/jamacardio.2016.3311
Dudink, E. A. et al. The biomarkers NT-proBNP and CA-125 are elevated in patients with idiopathic atrial fibrillation. J. Atr. Fibrillation 11, 2058 (2018).
pubmed: 31139280
pmcid: 6533832
doi: 10.4022/jafib.2058
Galie, N. et al. 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: the Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur. Heart J. 37, 67–119 (2016).
pubmed: 26320113
doi: 10.1093/eurheartj/ehv317
Kovacs, G. et al. Definition, clinical classification and initial diagnosis of pulmonary hypertension: updated recommendations from the Cologne Consensus Conference 2018. Int. J. Cardiol. 272S, 11–19 (2018).
pubmed: 30219257
doi: 10.1016/j.ijcard.2018.08.083
Hoeper, M. M. et al. A global view of pulmonary hypertension. Lancet Respir. Med. 4, 306–322 (2016).
pubmed: 26975810
doi: 10.1016/S2213-2600(15)00543-3
Lewis, G. D. et al. Pulmonary vascular hemodynamic response to exercise in cardiopulmonary diseases. Circulation 128, 1470–1479 (2013).
pubmed: 24060943
doi: 10.1161/CIRCULATIONAHA.112.000667
Helgeson, S. A., Imam, J. S., Moss, J. E., Hodge, D. O. & Burger, C. D. Comparison of brain natriuretic peptide levels to simultaneously obtained right heart hemodynamics in stable outpatients with pulmonary arterial hypertension. Diseases 6, E33 (2018).
pubmed: 29723983
doi: 10.3390/diseases6020033
Benza, R. L. et al. Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation 122, 164–172 (2010).
pubmed: 20585012
doi: 10.1161/CIRCULATIONAHA.109.898122
Galie, N. et al. 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. Rev. Esp. Cardiol. 69, 177 (2016).
pubmed: 26837729
doi: 10.1016/j.recesp.2016.01.002
Bender, A. T. & Beavo, J. A. Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol. Rev. 58, 488–520 (2006).
pubmed: 16968949
doi: 10.1124/pr.58.3.5
Hobbs, A. J. et al. Neprilysin inhibition for pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled, proof-of-concept trial. Br. J. Pharmacol. 176, 1251–1267 (2019).
pubmed: 30761523
pmcid: 7651846
doi: 10.1111/bph.14621
Baliga, R. S. et al. Synergy between natriuretic peptides and phosphodiesterase 5 inhibitors ameliorates pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med. 178, 861–869 (2008).
pubmed: 18689467
pmcid: 2643218
doi: 10.1164/rccm.200801-121OC
Baliga, R. S. et al. Intrinsic defence capacity and therapeutic potential of natriuretic peptides in pulmonary hypertension associated with lung fibrosis. Br. J. Pharmacol. 171, 3463–3475 (2014).
pubmed: 24641440
pmcid: 4105933
doi: 10.1111/bph.12694
Wilkins, M. R. et al. Recent advances in pulmonary arterial hypertension. F1000Res. 7, 1128 (2018).
doi: 10.12688/f1000research.14984.1
Ponikowski, P. et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur. Heart J. 37, 2129–2200 (2016).
pubmed: 27206819
doi: 10.1093/eurheartj/ehw128
Hildebrandt, P. et al. Age-dependent values of N-terminal pro-B-type natriuretic peptide are superior to a single cut-point for ruling out suspected systolic dysfunction in primary care. Eur. Heart J. 31, 1881–1889 (2010).
pubmed: 20519241
doi: 10.1093/eurheartj/ehq163
Januzzi, J. L. et al. NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the International Collaborative of NT-proBNP study. Eur. Heart J. 27, 330–337 (2006).
pubmed: 16293638
doi: 10.1093/eurheartj/ehi631
Maisel, A. S. et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N. Engl. J. Med. 347, 161–167 (2002).
pubmed: 12124404
doi: 10.1056/NEJMoa020233
Fernandez-Ruiz, I. Mechanisms of sacubitril-valsartan benefit in HFrEF. Nat. Rev. Cardiol. 16, 648 (2019).
pubmed: 31537918
doi: 10.1038/s41569-019-0282-2
McMurray, J. J. et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N. Engl. J. Med. 371, 993–1004 (2014).
pubmed: 25176015
doi: 10.1056/NEJMoa1409077
Balmforth, C. et al. Outcomes and effect of treatment according to etiology in HFrEF: an analysis of PARADIGM-HF. JACC Heart Fail. 7, 457–465 (2019).
pubmed: 31078482
doi: 10.1016/j.jchf.2019.02.015
Packer, M. et al. Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure. Circulation 131, 54–61 (2015).
pubmed: 25403646
doi: 10.1161/CIRCULATIONAHA.114.013748
Ibrahim, N. E. et al. Effect of neprilysin inhibition on various natriuretic peptide assays. J. Am. Coll. Cardiol. 73, 1273–1284 (2019).
pubmed: 30898202
doi: 10.1016/j.jacc.2018.12.063
Lainchbury, J. G. et al. Regional plasma levels of cardiac peptides and their response to acute neutral endopeptidase inhibition in man. Clin. Sci. 95, 547–555 (1998).
doi: 10.1042/cs0950547
Zile, M. R. et al. Prognostic implications of changes in N-terminal pro-B-type natriuretic peptide in patients with heart failure. J. Am. Coll. Cardiol. 68, 2425–2436 (2016).
pubmed: 27908347
doi: 10.1016/j.jacc.2016.09.931
Testa, M. et al. Circulating levels of cytokines and their endogenous modulators in patients with mild to severe congestive heart failure due to coronary artery disease or hypertension. J. Am. Coll. Cardiol. 28, 964–971 (1996).
pubmed: 8837575
doi: 10.1016/S0735-1097(96)00268-9
Yucel, T., Memis, D., Karamanlioglu, B., Sut, N. & Yuksel, M. The prognostic value of atrial and brain natriuretic peptides, troponin I and C-reactive protein in patients with sepsis. Exp. Clin. Cardiol. 13, 183–188 (2008).
pubmed: 19343164
pmcid: 2663482
D’Elia, E. et al. Neprilysin inhibition in heart failure: mechanisms and substrates beyond modulating natriuretic peptides. Eur. J. Heart Fail. 19, 710–717 (2017).
pubmed: 28326642
doi: 10.1002/ejhf.799
Jhund, P. S. & McMurray, J. J. The neprilysin pathway in heart failure: a review and guide on the use of sacubitril/valsartan. Heart 102, 1342–1347 (2016).
pubmed: 27207980
doi: 10.1136/heartjnl-2014-306775
Miners, J. S., Barua, N., Kehoe, P. G., Gill, S. & Love, S. Aβ-degrading enzymes: potential for treatment of Alzheimer disease. J. Neuropathol. Exp. Neurol. 70, 944–959 (2011).
pubmed: 22002425
doi: 10.1097/NEN.0b013e3182345e46
Cannon, J. A. et al. Dementia-related adverse events in PARADIGM-HF and other trials in heart failure with reduced ejection fraction. Eur. J. Heart Fail. 19, 129–137 (2017).
pubmed: 27868321
doi: 10.1002/ejhf.687
Cannon, J. A., McMurray, J. J. & Quinn, T. J. ‘Hearts and minds’: association, causation and implication of cognitive impairment in heart failure. Alzheimers Res. Ther. 7, 22 (2015).
pubmed: 25722749
pmcid: 4342092
doi: 10.1186/s13195-015-0106-5
Pandharipande, P. P. et al. Long-term cognitive impairment after critical illness. N. Engl. J. Med. 369, 1306–1316 (2013).
pubmed: 24088092
pmcid: 3922401
doi: 10.1056/NEJMoa1301372
Solomon, S. D. et al. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. N. Engl. J. Med. 381, 1609–1620 (2019).
pubmed: 31475794
doi: 10.1056/NEJMoa1908655
Januzzi, J. L. Jr et al. Association of change in N-terminal pro-B-type natriuretic peptide following initiation of sacubitril-valsartan treatment with cardiac structure and function in patients with heart failure with reduced ejection fraction. JAMA 322, 1085–1095 (2019).
pmcid: 6724151
doi: 10.1001/jama.2019.12821
pubmed: 31475295
Desai, A. S. et al. Effect of sacubitril-valsartan vs enalapril on aortic stiffness in patients with heart failure and reduced ejection fraction: a randomized clinical trial. JAMA 322, 1077–1084 (2019).
pmcid: 6749534
doi: 10.1001/jama.2019.12843
pubmed: 31475296
Schelbert, E. B. et al. Myocardial fibrosis quantified by extracellular volume is associated with subsequent hospitalization for heart failure, death, or both across the spectrum of ejection fraction and heart failure stage. J. Am. Heart Assoc. 4, e002613 (2015).
pubmed: 26683218
pmcid: 4845263
doi: 10.1161/JAHA.115.002613
Gonzalez, A., Schelbert, E. B., Diez, J. & Butler, J. Myocardial interstitial fibrosis in heart failure: biological and translational perspectives. J. Am. Coll. Cardiol. 71, 1696–1706 (2018).
pubmed: 29650126
doi: 10.1016/j.jacc.2018.02.021
Bishop, J. E. & Laurent, G. J. Collagen turnover and its regulation in the normal and hypertrophying heart. Eur. Heart J. 16 (Suppl. C), 38–44 (1995).
pubmed: 7556271
doi: 10.1093/eurheartj/16.suppl_C.38
Ellmers, L. J. et al. Ventricular expression of natriuretic peptides in Npr1
pubmed: 12124219
doi: 10.1152/ajpheart.00677.2001
Zile, M. R. et al. Effects of sacubitril/valsartan on biomarkers of extracellular matrix regulation in patients with HFrEF. J. Am. Coll. Cardiol. 73, 795–806 (2019).
pubmed: 30784673
doi: 10.1016/j.jacc.2018.11.042
Pitt, B. et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study investigators. N. Engl. J. Med. 341, 709–717 (1999).
pubmed: 10471456
doi: 10.1056/NEJM199909023411001
Zannad, F., Alla, F., Dousset, B., Perez, A. & Pitt, B. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the Randomized Aldactone Evaluation Study (RALES). Circulation 102, 2700–2706 (2000).
pubmed: 11094035
doi: 10.1161/01.CIR.102.22.2700
Pitt, B. et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N. Engl. J. Med. 348, 1309–1321 (2003).
pubmed: 12668699
doi: 10.1056/NEJMoa030207
Iraqi, W. et al. Extracellular cardiac matrix biomarkers in patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) study. Circulation 119, 2471–2479 (2009).
pubmed: 19398668
doi: 10.1161/CIRCULATIONAHA.108.809194
Zannad, F. et al. Eplerenone in patients with systolic heart failure and mild symptoms. N. Engl. J. Med. 364, 11–21 (2011).
pubmed: 21073363
doi: 10.1056/NEJMoa1009492
Pankow, K. et al. Structural substrate conditions required for neutral endopeptidase-mediated natriuretic peptide degradation. J. Mol. Biol. 393, 496–503 (2009).
pubmed: 19686760
doi: 10.1016/j.jmb.2009.08.025
Shen, L., Jhund, P. S. & McMurray, J. J. V. Declining risk of sudden death in heart failure. N. Engl. J. Med. 377, 1794–1795 (2017).
pubmed: 29091558
doi: 10.1056/NEJMoa1609758
Nguyen, M. N., Kiriazis, H., Gao, X. M. & Du, X. J. Cardiac fibrosis and arrhythmogenesis. Compr. Physiol. 7, 1009–1049 (2017).
pubmed: 28640451
doi: 10.1002/cphy.c160046
Liu, C. Y. et al. Association of elevated NT-proBNP with myocardial fibrosis in the Multi-Ethnic Study of Atherosclerosis (MESA). J. Am. Coll. Cardiol. 70, 3102–3109 (2017).
pubmed: 29268924
pmcid: 6561089
doi: 10.1016/j.jacc.2017.10.044
Ramos, H. R., Birkenfeld, A. L. & de Bold, A. J. Interacting disciplines: cardiac natriuretic peptides and obesity: perspectives from an endocrinologist and a cardiologist. Endocr. Connect. 4, R25–R36 (2015).
pubmed: 26115665
pmcid: 4485177
doi: 10.1530/EC-15-0018
Pivovarova, O. et al. Insulin up-regulates natriuretic peptide clearance receptor expression in the subcutaneous fat depot in obese subjects: a missing link between CVD risk and obesity? J. Clin. Endocrinol. Metab. 97, E731–E739 (2012).
pubmed: 22419733
doi: 10.1210/jc.2011-2839
Nakatsuji, H. et al. Reciprocal regulation of natriuretic peptide receptors by insulin in adipose cells. Biochem. Biophys. Res. Commun. 392, 100–105 (2010).
pubmed: 20059960
doi: 10.1016/j.bbrc.2010.01.008
Sarzani, R., Dessì-Fulgheri, P., Paci, V. M., Espinosa, E. & Rappelli, A. Expression of natriuretic peptide receptors in human adipose and other tissues. J. Endocrinol. Invest. 19, 581–585 (1996).
pubmed: 8957740
doi: 10.1007/BF03349021
Standeven, K. F. et al. Neprilysin, obesity and the metabolic syndrome. Int. J. Obes. 35, 1031–1040 (2011).
doi: 10.1038/ijo.2010.227
Bachmann, K. N. et al. Acute effects of insulin on circulating natriuretic peptide levels in humans. PLoS One 13, e0196869 (2018).
pubmed: 29758041
pmcid: 5951576
doi: 10.1371/journal.pone.0196869
Baldassarre, S. et al. NTproBNP in insulin-resistance mediated conditions: overweight/obesity, metabolic syndrome and diabetes. The population-based Casale Monferrato study. Cardiovasc. Diabetol. 16, 119 (2017).
pubmed: 28946871
pmcid: 5613356
doi: 10.1186/s12933-017-0601-z
Khan, A. M. et al. Cardiac natriuretic peptides, obesity, and insulin resistance: evidence from two community-based studies. J. Clin. Endocrinol. Metab. 96, 3242–3249 (2011).
pubmed: 21849523
pmcid: 3200240
doi: 10.1210/jc.2011-1182
Kim, F. et al. Brain natriuretic peptide and insulin resistance in older adults. Diabet. Med. 34, 235–238 (2017).
pubmed: 27101535
doi: 10.1111/dme.13139
Walford, G. A. et al. Circulating natriuretic peptide concentrations reflect changes in insulin sensitivity over time in the Diabetes Prevention Program. Diabetologia 57, 935–939 (2014).
pubmed: 24554005
pmcid: 4158711
doi: 10.1007/s00125-014-3183-2
Halfinger, B. et al. Unraveling the molecular complexity of O-glycosylated endogenous (N-terminal) pro-B-type natriuretic peptide forms in blood plasma of patients with severe heart failure. Clin. Chem. 63, 359–368 (2017).
pubmed: 28062629
doi: 10.1373/clinchem.2016.265397
Lewis, L. K. et al. ProBNP that is not glycosylated at threonine 71 is decreased with obesity in patients with heart failure. Clin. Chem. 65, 1115–1124 (2019).
pubmed: 31092393
doi: 10.1373/clinchem.2019.302547
Alcala, M., Calderon-Dominguez, M., Serra, D., Herrero, L. & Viana, M. Mechanisms of impaired brown adipose tissue recruitment in obesity. Front. Physiol. 10, 94 (2019).
pubmed: 30814954
pmcid: 6381290
doi: 10.3389/fphys.2019.00094
Cypess, A. M. et al. Identification and importance of brown adipose tissue in adult humans. N. Engl. J. Med. 360, 1509–1517 (2009).
pubmed: 19357406
pmcid: 2859951
doi: 10.1056/NEJMoa0810780
Saito, M. et al. High incidence of metabolically active brown adipose tissue in healthy adult humans: effects of cold exposure and adiposity. Diabetes 58, 1526–1531 (2009).
pubmed: 19401428
pmcid: 2699872
doi: 10.2337/db09-0530
van Marken Lichtenbelt, W. D. et al. Cold-activated brown adipose tissue in healthy men. N. Engl. J. Med. 360, 1500–1508 (2009).
pubmed: 19357405
doi: 10.1056/NEJMoa0808718
Zingaretti, M. C. et al. The presence of UCP1 demonstrates that metabolically active adipose tissue in the neck of adult humans truly represents brown adipose tissue. FASEB J. 23, 3113–3120 (2009).
pubmed: 19417078
doi: 10.1096/fj.09-133546
Wang, T. J. et al. Impact of obesity on plasma natriuretic peptide levels. Circulation 109, 594–600 (2004).
pubmed: 14769680
doi: 10.1161/01.CIR.0000112582.16683.EA
Seferovic, J. P. et al. Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial. Lancet Diabetes Endocrinol. 5, 333–340 (2017).
pubmed: 28330649
pmcid: 5534167
doi: 10.1016/S2213-8587(17)30087-6
Collins, S. A heart–adipose tissue connection in the regulation of energy metabolism. Nat. Rev. Endocrinol. 10, 157–163 (2014).
pubmed: 24296515
doi: 10.1038/nrendo.2013.234
Glode, A. et al. Divergent effects of a designer natriuretic peptide CD-NP in the regulation of adipose tissue and metabolism. Mol. Metab. 6, 276–287 (2017).
pubmed: 28271034
pmcid: 5323888
doi: 10.1016/j.molmet.2016.12.010
Rorth, R. et al. The prognostic value of troponin T and N-terminal pro B-type natriuretic peptide, alone and in combination, in heart failure patients with and without diabetes. Eur. J. Heart Fail. 21, 40–49 (2019).
pubmed: 30537261
doi: 10.1002/ejhf.1359
Abrahamsson, N., Engstrom, B. E., Sundbom, M. & Karlsson, F. A. Gastric bypass surgery elevates NT-ProBNP levels. Obes. Surg. 23, 1421–1426 (2013).
pubmed: 23456799
doi: 10.1007/s11695-013-0889-z
Gabrielsen, A. M. et al. The effect of surgical and non-surgical weight loss on N-terminal pro-B-type natriuretic peptide and its relation to obstructive sleep apnea and pulmonary function. BMC Res. Notes 9, 440 (2016).
pubmed: 27619215
pmcid: 5020450
doi: 10.1186/s13104-016-2241-x
Docherty, N. G., Fandriks, L., le Roux, C. W., Hallersund, P. & Werling, M. Urinary sodium excretion after gastric bypass surgery. Surg. Obes. Relat. Dis. 13, 1506–1514 (2017).
pubmed: 28571926
doi: 10.1016/j.soard.2017.04.002
Belluardo, P. et al. Lack of activation of molecular forms of the BNP system in human grade 1 hypertension and relationship to cardiac hypertrophy. Am. J. Physiol. Heart Circ. Physiol. 291, H1529–H1535 (2006).
pubmed: 16648193
doi: 10.1152/ajpheart.00107.2006
Macheret, F. et al. Human hypertension is characterized by a lack of activation of the antihypertensive cardiac hormones ANP and BNP. J. Am. Coll. Cardiol. 60, 1558–1565 (2012).
pubmed: 23058313
pmcid: 4041520
doi: 10.1016/j.jacc.2012.05.049
Seven, E. et al. Higher serum concentrations of N-terminal pro-B-type natriuretic peptide associate with prevalent hypertension whereas lower associate with incident hypertension. PLoS One 10, e0117864 (2015).
pubmed: 25658326
pmcid: 4320109
doi: 10.1371/journal.pone.0117864
Newton-Cheh, C. et al. Association of common variants in NPPA and NPPB with circulating natriuretic peptides and blood pressure. Nat. Genet. 41, 348–353 (2009).
pubmed: 19219041
pmcid: 2664511
doi: 10.1038/ng.328
Soares-da-Silva, P. & Fernandes, M. H. Synthesis and metabolism of dopamine in the kidney. Effects of sodium chloride, monoamine oxidase inhibitors and α-human atrial natriuretic peptide. Am. J. Hypertens. 3, 7S–10S (1990).
pubmed: 2143389
doi: 10.1093/ajh/3.6.7S
Pandey, K. N. Molecular and genetic aspects of guanylyl cyclase natriuretic peptide receptor-A in regulation of blood pressure and renal function. Physiol. Genomics 50, 913–928 (2018).
pubmed: 30169131
pmcid: 6293115
doi: 10.1152/physiolgenomics.00083.2018
Kouyoumdzian, N. M. et al. Atrial natriuretic peptide stimulates dopamine tubular transport by organic cation transporters: a novel mechanism to enhance renal sodium excretion. PLoS One 11, e0157487 (2016).
pubmed: 27392042
pmcid: 4938554
doi: 10.1371/journal.pone.0157487
Gupta, D. K., de Lemos, J. A., Ayers, C. R., Berry, J. D. & Wang, T. J. Racial differences in natriuretic peptide levels: the Dallas Heart Study. JACC Heart Fail. 3, 513–519 (2015).
pubmed: 26071618
pmcid: 4498971
doi: 10.1016/j.jchf.2015.02.008
Seidelmann, S. B. et al. An NPPB promoter polymorphism associated with elevated N-terminal pro-B-type natriuretic peptide and lower blood pressure, hypertension, and mortality. J. Am. Heart Assoc. 6, e005257 (2017).
pubmed: 28341776
pmcid: 5533018
doi: 10.1161/JAHA.116.005257
Mogelvang, R. et al. Discriminating between cardiac and pulmonary dysfunction in the general population with dyspnea by plasma pro-B-type natriuretic peptide. J. Am. Coll. Cardiol. 50, 1694–1701 (2007).
pubmed: 17950153
doi: 10.1016/j.jacc.2007.07.073
Modin, D. et al. Prognostic value of left atrial functional measures in heart failure with reduced ejection fraction. J. Card. Fail. 25, 87–96 (2019).
pubmed: 30472280
doi: 10.1016/j.cardfail.2018.11.016
Saito, Y. Roles of atrial natriuretic peptide and its therapeutic use. J. Cardiol. 56, 262–270 (2010).
pubmed: 20884176
doi: 10.1016/j.jjcc.2010.08.001
O’Connor, C. M. et al. Effect of nesiritide in patients with acute decompensated heart failure. N. Engl. J. Med. 365, 32–43 (2011).
pubmed: 21732835
doi: 10.1056/NEJMoa1100171
Buglioni, A. & Burnett, J. C. Jr. New pharmacological strategies to increase cGMP. Annu. Rev. Med. 67, 229–243 (2016).
pubmed: 26473417
doi: 10.1146/annurev-med-052914-091923
Cataliotti, A., Costello-Boerrigter, L. C., Chen, H. H., Textor, S. C. & Burnett, J. C. Jr. Sustained blood pressure-lowering actions of subcutaneous B-type natriuretic peptide (nesiritide) in a patient with uncontrolled hypertension. Mayo Clin. Proc. 87, 413–415 (2012).
pubmed: 22469356
pmcid: 3497998
doi: 10.1016/j.mayocp.2012.02.003
Cataliotti, A. et al. Oral human brain natriuretic peptide activates cyclic guanosine 3′,5′-monophosphate and decreases mean arterial pressure. Circulation 112, 836–840 (2005).
pubmed: 16061734
doi: 10.1161/CIRCULATIONAHA.105.538520
Strohl, W. R. Fusion proteins for half-life extension of biologics as a strategy to make biobetters. BioDrugs 29, 215–239 (2015).
pubmed: 26177629
pmcid: 4562006
doi: 10.1007/s40259-015-0133-6
de Bold, M. K. et al. Characterization of a long-acting recombinant human serum albumin-atrial natriuretic factor (ANF) expressed in Pichia pastoris. Regul. Pept. 175, 7–10 (2012).
pubmed: 22296859
doi: 10.1016/j.regpep.2012.01.005
Ding, Y. et al. The effects of fusion structure on the expression and bioactivity of human brain natriuretic peptide (BNP) albumin fusion proteins. Curr. Pharm. Biotechnol. 15, 856–863 (2014).
pubmed: 25307015
doi: 10.2174/1389201015666141012182106
Sezai, A. et al. Continuous low-dose infusion of human atrial natriuretic peptide in patients with left ventricular dysfunction undergoing coronary artery bypass grafting: the NU-HIT (Nihon University working group study of low-dose Human ANP Infusion Therapy during cardiac surgery) for left ventricular dysfunction. J. Am. Coll. Cardiol. 55, 1844–1851 (2010).
pubmed: 20413036
doi: 10.1016/j.jacc.2009.11.085
McKie, P. M. et al. A human atrial natriuretic peptide gene mutation reveals a novel peptide with enhanced blood pressure-lowering, renal-enhancing, and aldosterone-suppressing actions. J. Am. Coll. Cardiol. 54, 1024–1032 (2009).
pubmed: 19729120
pmcid: 2803058
doi: 10.1016/j.jacc.2009.04.080
Mezo, A. R. et al. Atrial natriuretic peptide-Fc, ANP-Fc, fusion proteins: semisynthesis, in vitro activity and pharmacokinetics in rats. Bioconjug. Chem. 23, 518–526 (2012).
pubmed: 22263969
doi: 10.1021/bc200592c
Zhang, S. M. et al. A new chimeric natriuretic peptide, CNAAC, for the treatment of left ventricular dysfunction after myocardial infarction. Sci. Rep. 7, 10099 (2017).
pubmed: 28855643
pmcid: 5577105
doi: 10.1038/s41598-017-10748-6
McGregor, A., Richards, M., Espiner, E. A., Yandle, T. G. & Ikram, H. Brain natriuretic peptide administered to man: actions and metabolism. J. Clin. Endocrinol. Metab. 70, 1103–1107 (1990).
pubmed: 2156886
doi: 10.1210/jcem-70-4-1103
Chen, H. H. et al. Novel protein therapeutics for systolic heart failure: chronic subcutaneous B-type natriuretic peptide. J. Am. Coll. Cardiol. 60, 2305–2312 (2012).
pubmed: 23122795
pmcid: 3555560
doi: 10.1016/j.jacc.2012.07.056
Wang, W., Ou, Y. & Shi, Y. AlbuBNP, a recombinant B-type natriuretic peptide and human serum albumin fusion hormone, as a long-term therapy of congestive heart failure. Pharm. Res. 21, 2105–2111 (2004).
pubmed: 15587934
doi: 10.1023/B:PHAM.0000048203.30568.81
Dickey, D. M. & Potter, L. R. Dendroaspis natriuretic peptide and the designer natriuretic peptide, CD-NP, are resistant to proteolytic inactivation. J. Mol. Cell. Cardiol. 51, 67–71 (2011).
pubmed: 21459096
pmcid: 4855506
doi: 10.1016/j.yjmcc.2011.03.013
Martin, F. L. et al. CD-NP: a novel engineered dual guanylyl cyclase activator with anti-fibrotic actions in the heart. PLoS One 7, e52422 (2012).
pubmed: 23272242
pmcid: 3525541
doi: 10.1371/journal.pone.0052422
Martin, F. L. et al. Experimental mild renal insufficiency mediates early cardiac apoptosis, fibrosis, and diastolic dysfunction: a kidney-heart connection. Am. J. Physiol. Regul. Integr. Comp. Physiol. 302, R292–R299 (2012).
pubmed: 22071162
doi: 10.1152/ajpregu.00194.2011
Kawakami, R. et al. A human study to evaluate safety, tolerability, and cyclic GMP activating properties of cenderitide in subjects with stable chronic heart failure. Clin. Pharmacol. Ther. 104, 546–552 (2018).
pubmed: 29226471
pmcid: 5995613
doi: 10.1002/cpt.974
Bruneau, B. G. Atrial natriuretic factor in the developing heart: a signpost for cardiac morphogenesis. Can. J. Physiol. Pharmacol. 89, 533–537 (2011).
pubmed: 21806510
doi: 10.1139/y11-051
Ichiki, T., Dzhoyashvili, N. & Burnett, J. C. Jr. Natriuretic peptide based therapeutics for heart failure: cenderitide: a novel first-in-class designer natriuretic peptide. Int. J. Cardiol. 281, 166–171 (2019).
pubmed: 29941213
doi: 10.1016/j.ijcard.2018.06.002